Gemcitabine and cisplatin combination regimen in patients with anthracycline-and taxane-pretreated metastatic breast cancer

Medical Oncology

Volumn 29, Issue 1, 2012, Pages 56-61

  Wang, Tao ^a   Zhang, Shaohua ^a   Zeng, Min ^a   Lu, Xinyou ^a   Shen, Ge ^a   Wu, Shikai ^a   Song, Santai ^a   Jiang, Zefei ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Cisplatin; Gemcitabine; Metastatic breast cancer

Indexed keywords

ANTHRACYCLINE; CISPLATIN; GEMCITABINE; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DIARRHEA; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; SALVAGE THERAPY; TAXOIDS; TREATMENT OUTCOME;

EID: 84864046074     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9814-7     Document Type: Article

References (23)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137-50. (Pubitemid 46655601)
2. Vici P, Di Lauro L, Sergi D, Foggi P, Viola G, Mottolese M, et al. A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines. Oncology. 2008;75:175-81.
3. Crown J. Nonanthracycline containing docetaxel-based combinations in metastatic breast cancer. Oncologist. 2001;6 S3:17-21. (Pubitemid 32423181)
4. Ravdin PM, Burris HA 3rd, Cook G, Eisenberg P, Kane M, Bierman WA, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol. 1995;13:2879-85.
5. Vici P, Belli F, Di Lauro L, Amodio A, Conti F, Foggi P, et al. Docetaxel in patients with anthracycline-resistant advanced breast cancer. Oncology. 2001;60:60-5. (Pubitemid 32041433)
6. Valero V, Hortobagyi GN. Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? J Clin Oncol. 2003;21:959-62. (Pubitemid 46594120)
7. Somali I, Alacacioglu A, Tarhan MO, Meydan N, Erten C, Usalp S, Yilmaz U. Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer. Chemotherapy. 2009;55:155-60.
8. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL. Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol. 1995;13:2731-6.
9. Spielmann M, Llombart-Cussac A, Kalla S, Espié M, Namer M, Ferrero JM, et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology. 2001;60:303-7. (Pubitemid 32623443)
10. Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology. 2002;62:2-8. (Pubitemid 34124219)
11. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcit-abine in vitro. Clin Cancer Res. 1996;2:521-30. (Pubitemid 26099172)
12. van Moorsel CJ, Kroep JR, Pinedo HM, Veerman G, Voorn DA, Postmus PE, et al. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann Oncol. 1999;10:441-8. (Pubitemid 29236422)
13. Nagourney RA, Link JS, Blitzer JB, Forstho VC, Evans SS. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol. 2000; 18:2245-9. (Pubitemid 30350216)
14. Mohran TZ. Gemcitabine and Cisplatin combination chemotherapy as a first-line treatment in patients with metastatic breast cancer. J Egypt Natl Canc Inst. 2004;16:8-14.
15. Heinemann V, Stemmler HJ, Wohlrab A, Bosse D, Losem C, Kahlert S, Rauthe G. High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline-and taxane-pre-treated metastatic breast cancer. Cancer Chemother Pharmacol. 2006;57:640-6. (Pubitemid 43237849)
16. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10. (Pubitemid 19099520)
17. Rivera E. Implications of anthracycline-resistant and taxane-resistant metastatic breast cancer and new therapeutic options. Breast J. 2010;16:252-63.
18. Burch PA, Mailliard JA, Hillman DW, Perez EA, Krook JE, Rowland KM, et al. Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial. Am J Clin Oncol. 2005;28:195-200.
19. Seo JH, Oh SC, Choi CW, Kim BS, Shin SW, Kim YH, et al. Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer. Cancer Chemother Pharmacol. 2007;59:269-74. (Pubitemid 44885156)
20. Sánchez-Escribano Morcuende R, Alés-Mart'inez JE, Aramburo González PM. Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane- anthracycline-containing regimens. Clin Transl Oncol. 2007;9:459-64.
21. Kim JH, Oh SY, Kwon HC, Lee S, Kim SH, Kim DC, et al. Phase II study of gemcitabine plus cisplatin in patients with anthracy-cline-and taxane-pretreated metastatic breast cancer. Cancer Res Treat. 2008;40:101-5.
22. Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz HJ, et al. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol. 2009;27:2163-9.
23. Bishop DK, Ear U, Bhattacharyya A, Calderone C, Beckett M, Weichselbaum RR, Shinohara A. Xrcc3 is required for assembly of Rad51 complexes in vivo. J Biol Chem. 1998;273:21482-8. (Pubitemid 28405315)